On December 2, 2024, Lundbeck announced that it had successfully completed the transaction to acquire Longboard Pharmaceuticals. With the completion of this transaction, Longboard has become a wholly owned subsidiary of Lundbeck, and this page will consequently no longer be used actively. Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. For future updates and more information about Lundbeck’s research and our global organization, please follow the Lundbeck LinkedIn page. https://lnkd.in/dpYa4WXQ
Longboard Pharmaceuticals
Biotechnology Research
La Jolla, CA 11,201 followers
We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases.
About us
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. Longboard recently reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants ages 12 to 65 years old with Developmental and Epileptic Encephalopathies (DEEs), including Lennox-Gastaut syndrome, Dravet syndrome and other DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions.
- Website
-
http://www.longboardpharma.com/
External link for Longboard Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- La Jolla, CA
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
Get directions
4275 Executive Square
Suite 950
La Jolla, CA 92037, US
Employees at Longboard Pharmaceuticals
Updates
-
We are pleased to announce the initiation of our Ph 3 DEEp OCEAN Study for individuals living with Developmental and Epileptic Encephalopathies (DEEs). We are very proud of the team for their hard work and dedication to the DEEp Program! https://bit.ly/3YKaNSk
-
-
We are thrilled to be the first partner in the Allies in Research Program with the Pediatric Epilepsy Research Consortium! We look forward to collaborating with this amazing network to support the pediatric epilepsy community.
PERC is pleased to announce Longboard Pharmaceuticals as our first participant in the Allies in Research Program supporting the research mission of PERC! Learn more about the AIR program here: https://lnkd.in/gCSNPNKw
-
-
Another great accomplishment for our team! We are so pleased to announce that we initiated our Phase 3 DEEp Program - starting with DEEp SEA in #DravetSyndrome. Please click here for additional detail. https://bit.ly/4eDV4uj
-
-
Today, we announced Rare Pediatric Disease and Orphan Drug designations for bexicaserin in Dravet syndrome - another terrific regulatory milestone! Additional details available here https://bit.ly/3XzAKna
-
-
Thank you to everyone who attended our R&D Day in NYC yesterday! The replay is available here. https://bit.ly/3OEgIEd
-
-
Thank you to Patrick R. Trucchio & H.C. Wainwright & Co., LLC for hosting us at the 26th Annual Global Investor Conference. A webcast of our fireside chat with our CFO, Brandi Roberts is available here. https://bit.ly/4dUchzZ #HCWainwrightGlobal
-
-
Today, we announced positive interim results from our ongoing open-label extension (OLE) of the PACIFIC Study evaluating bexicaserin in participants with DEEs. Our CMO, Randall Kaye, presented these data at the International League Against Epilepsy 15th European Epilepsy Congress. For more detail on the OLE results visit the following link https://bit.ly/4ed1KPP #EEC2024 #EEC
-
-
We are #hiring in the US, EU, AUS and more! Please see our open positions here: https://lnkd.in/gBVEBrXx #clinicaloperations #clincialpharmacology #medicalaffairs #biotechjobs
Longboard Life - Longboard Pharmaceuticals
https://www.longboardpharma.com
-
We are pleased to be chosen as one of the Best Places to Work in San Diego - Thank you to the San Diego Business Journal for this honor! At Longboard, we foster a company culture that is both collaborative and inclusive, and we believe that is essential for innovation and success. We are driven by our common mission to develop novel, transformative medicines for people living with devastating neurological conditions.
-